Article Figures & Data
Figures
- Figure 1.
Sex differences in seizure parameters at two months after IHKA injection. A, Example seizure traces. B–D, Circles represent individual values of the average number of seizures per hour (B), average seizure duration (C), and average percent time in seizure (D) for each mouse plotted with mean ± SEM in black lines. *p < 0.05, **p < 0.01, ***p < 0.001 two-way ANOVA and Tukey’s post hoc tests.
- Figure 2.
Higher seizure duration in females at four months after IHKA injection. A–C, Circles represent individual values of the average number of seizures per hour (A), average seizure duration (B), and average percent time in seizure (C) for each mouse plotted with mean ± SEM in black lines. *p < 0.05, **p < 0.01 two-way ANOVA and Tukey’s post hoc tests.
- Figure 3.
Seizure burden is elevated in IHKA-L females on diestrus two months after IHKA injection. A–C, Circles represent individual values of the average number of seizures per hour (A), average seizure duration (B), and average percent time in seizure (C) for each IHKA female, plotted with mean ± SEM in black lines. *p < 0.05, **p < 0.01 two-sample t test or Wilcoxon rank-sum test based on data normality.
- Figure 4.
Lateralization and cycle stage effects on seizure burden in females are dampened at four months after IHKA injection. A–C, Circles represent individual values of the average number of seizures per hour (A), average seizure duration (B), and average percent time in seizure (C) for each IHKA female, plotted with mean ± SEM in black lines.
- Figure 5.
Seizure burden severity is not correlated to the degree of granule cell dispersion at 4 mpi. A, Representative images of Nissl staining, illustrating granule cell dispersion, CA1 cell death, and damage from LFP electrode implantation. Scale bar = 1 mm. B, Proportions of mice in each group that did (colored bars) or did not (black bars) display granule cell dispersion by visual inspection. C, Relationship of the percent time in seizure as a function of the ipsilateral-to-contralateral (I:C) granule cell area ratio. Circles indicate individual mice. Solid lines indicate the linear regression of best fit.
- Figure 6.
Seizure burden severity is not correlated to the degree of estrous cycle disruption. Percent of time in seizure as a function of estrous cycle length for each mouse evaluated at two (left) and four months postinjection (right) in IHKA-L (top) and IHKA-R (bottom) groups. Circles indicate individual mice. Solid lines indicate the linear regression of best fit.
- Figure 7.
Circulating levels of ovarian hormones on diestrus are not correlated with seizure burden severity at 4 mpi. A–C, Percentage of time spent in seizures as a function of serum progesterone (A), estradiol (B), and P4:E2 ratio (C) levels of hormones in circulation for each mouse in IHKA-L (left) and IHKA-R (right) groups. Circles indicate individual mice. Solid lines indicate the linear regression of best fit.
Tables
Figure Graph Data structure Test p value 95% confidence interval Figure 1B IHKA-L males vs females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.005 23.96–38.42 and 41.46–57.72 Figure 1B IHKA-R males vs females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.005 14.60–41.80 and 33.88–42.66 Figure 1B IHKA-R males vs IHKA-L females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.002 14.60–41.80 and 41.46–57.72 Figure 1C IHKA-L males vs females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.02 11.94–17.58 and 17.01–21.67 Figure 1C IHKA-R males vs females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.02 9.36–17.16 and 15.65–20.51 Figure 1C IHKA-R males vs IHKA-L females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.03 9.36–17.16 and 17.01–21.67 Figure 1D IHKA-L males vs females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.0007 9.43–16.87 and 20.87–20.71 Figure 1D IHKA-R males vs females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.0007 5.03–17.23 and 15.90–23.00 Figure 1D IHKA-R males vs IHKA-L females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.0004 5.03–17.23 and 20.87–20.71 Figure 2B IHKA-L males vs females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.006 11.16–16.92 and 15.94–20.22 Figure 2B IHKA-R males vs females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.006 10.25–17.07 and 16.85–21.25 Figure 2B IHKA-L males vs IHKA-R females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.03 10.25–17.07 and 15.94–20.22 Figure 2C IHKA-L males vs females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.02 6.58–16.78 and 12.81–20.15 Figure 2C IHKA-R males vs females Normally distributed Two-way ANOVA, Tukey’s post hoc test 0.02 6.27–13.29 and 14.67–22.19 Figure 3A Diestrus Normally distributed Two-sample t test 0.05 29.30–44.04 and 39.53–58.65 Figure 3A Estrus Normally distributed Two-sample t test 0.02 33.63–44.29 and 42.51–57.33 Figure 3B Diestrus Non-normal distribution Wilcoxon rank-sum test 0.04 15.13–21.63 and 19.37–27.37 Figure 3C Diestrus Non-normal distribution Wilcoxon rank-sum test 0.04 13.77–24.67 and 23.83–37.59
In this issue
